Similarly, a randomized, double-blind phase II trial assessed the safety, tolerability, and cognitive benefits of EGCG, a green tea polyphenol able to oxidize Keap1 cysteine residues and to downregulate BACH1, accelerating the NRF2-Keap1 complex disassociation and preventing BACH1-dependent ARE site occupation, in HD patients (ID: NCT01357681). The gene discussed is KEAP1; the disease is Huntington disease.